- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 11, 2023
Deals
Jan. 10 Quick Takes: AbbVie taps Anima for mRNA therapeutics
Plus updates from Alto, Union, AskBio-Recode, Phathom and more
BioCentury | Jan 15, 2022
Data Byte
The shingles vaccine pipeline
A growing list of early-stage competitors coming up behind the two approved products
BioCentury | Nov 6, 2021
Discovery & Translation
Pfizer’s pan-coronavirus oral antiviral; plus Myrio, Innovent, Spark and more
BioCentury’s roundup of translational news
BioCentury | May 17, 2021
Deals
May 17 Quick Takes: Antengene adds CD73 inhibitor to pipeline via Calithera deal; plus Aadi, Apellis, Charles River-Vigene, FDA and Sanofi-GSK
Seven months after its $360 million IPO on the Hong Kong stock exchange, Shanghai-based Antengene Corp. Ltd. (HKEX:6996) is building out its pipeline with exclusive, worldwide development and
BioCentury | Feb 13, 2021
Product Development
Howdy partner: MD Anderson’s evolving industry collaboration strategy
How the cancer center is choosing clinical trial partners and advancing new modalities
BioCentury | Dec 6, 2019
Targets & Mechanisms
Emerging immuno-oncology mechanisms at ASH 2019
Immune system biomarkers take center stage among emerging targets at ASH 2019
BioCentury | Jun 18, 2019
Clinical News
June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more
BioCentury | Apr 10, 2019
Distillery Therapeutics
Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma
BioCentury | Nov 15, 2018
Product R&D
Tempest takes PPAR alpha into cancer
Why Tempest thinks PPARα could succeed in cancer where IDO failed
Items per page:
1 - 10 of 58